CanaFarma Hemp Products Inc (CNFA) started May 2020 at .79 and closed the month at $1.23 with volume increasing every day. Since April 15th shares are up 100% as the CBD market finds new investors and becomes a port in the storm during the economic shut down of Covid-19. This is an industry-wide phenomenon as large Cannabis companies purchase cash flow companies in the CBD space.
The company launched in the middle of the Covid -19 virus economic shutdown and has done a remarkable job gaining new investors and increasing volume and liquidity in multiple markets, this is a true testament to the CBD business model during this 2020 growth period for products and services revolving around CBD.
CanaFarma (CNFA) trading volume continued to strengthen across multiple markets, from Canada to the German Borse, much of that is because they are a rare “cash producing” cannabis sector stock. The companies core skill set is Direct Marketing, and has had some success selling it’s Yooforic CBD Gum product, while keeping new product launches on track.
Many publicly-traded cannabis stocks are buying CBD companies to add cash flow. Leaders in the sector like Aurora (ACB) and others look to capture an expanded multiple that exists because investors are paying up hoping for legalization and a federal mandate for all weed stocks.
David Lonsdale, CEO of CanaFarma said, “We are very pleased with the performance of our metrics-based marketing model to date and look forward to applying the knowledge gained from our initial product sales as we look to scale up our marketing and sales efforts in the future.”
The Company takes a very methodical, metrics-based analytical approach to bring products to market. By testing in a microcosm, our marketing analysts are able to decipher which channels are generating the strongest results. We then mechanically eliminate those efforts that produced at a sub-par level, make adjustments to those that provided acceptable results, and capitalize on those strategies that performed at the highest levels. We then continue to add novel tests and repeat the same methodology.
